Ark Genomic Revolution Etf One Year Return
| ARKG Etf | USD 25.17 0.00 0.00% |
ARK Genomic Revolution fundamentals help investors to digest information that contributes to ARK Genomic's financial success or failures. It also enables traders to predict the movement of ARK Etf. The fundamental analysis module provides a way to measure ARK Genomic's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to ARK Genomic etf.
ARK |
ARK Genomic Revolution ETF One Year Return Analysis
ARK Genomic's One Year Return is the annualized return generated from holding a security for exactly 12 months. The measure is considered to be good short-term measures of fund performance. In other words, it represents the capital appreciation of fund investments over the last year. However when the market is volatile such as in recent years, One Year Return measure can be misleading.
More About One Year Return | All Equity Analysis
One Year Return | = | (Mean of Monthly Returns - 1) | X | 100% |
Current ARK Genomic One Year Return | (17.20) % |
Most of ARK Genomic's fundamental indicators, such as One Year Return, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, ARK Genomic Revolution is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Although One Year Fund Return indicator can give a sense of overall fund short-term potential, it is recommended to look at mid and long term return measure before selecting a particular fund or ETF. The great way to validate fund short-term performance is to compare it with other similar funds or ETFs for the same 12 months interval.
| Competition |
Based on the recorded statements, ARK Genomic Revolution has an One Year Return of -17.2%. This is 285.34% lower than that of the ARK ETF Trust family and significantly lower than that of the Health category. The one year return for all United States etfs is notably higher than that of the company.
ARK One Year Return Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses ARK Genomic's direct or indirect competition against its One Year Return to detect undervalued stocks with similar characteristics or determine the etfs which would be a good addition to a portfolio. Peer analysis of ARK Genomic could also be used in its relative valuation, which is a method of valuing ARK Genomic by comparing valuation metrics of similar companies.ARK Genomic is currently under evaluation in one year return as compared to similar ETFs.
Fund Asset Allocation for ARK Genomic
The fund invests 99.63% of asset under management in tradable equity instruments, with the rest of investments concentrated in various types of exotic instruments.Asset allocation divides ARK Genomic's investment portfolio among different asset categories to balance risk and reward by investing in a diversified mix of instruments that align with the investor's goals, risk tolerance, and time horizon. Mutual funds, which pool money from multiple investors to buy a diversified portfolio of securities, use asset allocation strategies to manage the risk and return of their portfolios.
Mutual funds allocate their assets by investing in a diversified portfolio of securities, such as stocks, bonds, cryptocurrencies and cash. The specific mix of these securities is determined by the fund's investment objective and strategy. For example, a stock mutual fund may invest primarily in equities, while a bond mutual fund may invest mainly in fixed-income securities. The fund's manager, responsible for making investment decisions, will buy and sell securities in the fund's portfolio as market conditions and the fund's objectives change.
ARK Fundamentals
| Price To Earning | 41.86 X | |||
| Price To Book | 3.26 X | |||
| Price To Sales | 7.63 X | |||
| Number Of Employees | 330 | |||
| Beta | 1.8 | |||
| Total Asset | 2.36 B | |||
| One Year Return | (17.20) % | |||
| Three Year Return | (25.60) % | |||
| Five Year Return | (5.60) % | |||
| Ten Year Return | 2.60 % | |||
| Net Asset | 2.36 B | |||
| Last Dividend Paid | 1.05 | |||
| Equity Positions Weight | 99.63 % |
About ARK Genomic Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze ARK Genomic Revolution's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ARK Genomic using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ARK Genomic Revolution based on its fundamental data. In general, a quantitative approach, as applied to this etf, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
When determining whether ARK Genomic Revolution is a strong investment it is important to analyze ARK Genomic's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact ARK Genomic's future performance. For an informed investment choice regarding ARK Etf, refer to the following important reports:Check out ARK Genomic Piotroski F Score and ARK Genomic Altman Z Score analysis. You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
The market value of ARK Genomic Revolution is measured differently than its book value, which is the value of ARK that is recorded on the company's balance sheet. Investors also form their own opinion of ARK Genomic's value that differs from its market value or its book value, called intrinsic value, which is ARK Genomic's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ARK Genomic's market value can be influenced by many factors that don't directly affect ARK Genomic's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ARK Genomic's value and its price as these two are different measures arrived at by different means. Investors typically determine if ARK Genomic is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ARK Genomic's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.